Business Context and Reporting Period
This Form 8-K filing by Conduit Pharmaceuticals Inc. (CDT) covers events occurring on November 22, 2024, and November 25, 2024. The company, an emerging growth company incorporated in Delaware, reported the entry into material definitive agreements involving the issuance of convertible debt instruments to address deferred commissions and amend existing senior secured notes.
Key Financial Metrics and Obligations
- Convertible Promissory Note (A.G.P.): Principal amount of $5,737,500 issued to A.G.P./Alliance Global Partners to evidence a deferred commission. Interest accrues at 5.5% per annum with a maturity date of November 25, 2025.
- Senior Secured Promissory Note (Nirland): Original principal of $2,650,000 (inclusive of a $500,000 original issuance discount) issued in August 2024. Amended on November 22, 2024.
- Conversion Terms:
- A.G.P. Note: Convertible at a fixed price of $0.10 per share (subject to adjustments and a $1.00 floor following significant reverse splits).
- Nirland Note: Conversion rate amended to 2.5 times the sum of principal and accrued interest divided by $0.10 per share (subject to similar adjustments and floors).
- Potential Dilution: Up to 58 million shares may be issued upon conversion of the A.G.P. Note and up to 75 million shares upon conversion of the Nirland Note.
Material Changes and Agreements
The filing details two primary financial transactions:
- Issuance of Convertible Note: The company formalized a $5,737,500 obligation to A.G.P. as a convertible note. Conversion is subject to Nasdaq stockholder approval rules and a 9.99% beneficial ownership limitation for the holder.
- Second Amendment to Nirland Note: The company amended its existing note with Nirland Limited. Key changes include:
- Conversion is now prohibited prior to stockholder approval.
- A penalty of $100,000 per day applies if a special stockholder meeting to approve conversion is not held by January 9, 2025.
- The conversion rate was increased to 2.5x the principal and accrued interest.
Outlook, Risks, and Contingencies
- Stockholder Approval Requirement: Both debt instruments require stockholder approval for full conversion under Nasdaq rules. The Nirland Note specifically imposes a strict deadline (January 9, 2025) for holding a special meeting to avoid daily penalties.
- Liquidity and Default Risk: The A.G.P. Note contains customary default provisions where the entire principal and accrued interest become immediately due upon certain Events of Default.
- Unregistered Securities: The potential shares issuable upon conversion (up to 133 million total) are unregistered under the Securities Act of 1933 and cannot be sold in the U.S. absent registration or an exemption.
- Reverse Split Sensitivity: Conversion prices are subject to adjustment if the company executes a reverse split greater than 10-to-1, with a floor price of $1.00 per share in such scenarios.
Investor Verification Checklist
- Verify the company's ability to schedule a special stockholder meeting before January 9, 2025, to avoid the $100,000 daily penalty on the Nirland Note.
- Confirm the current cash position and liquidity status to assess the ability to service the $5.7M A.G.P. note if conversion is delayed or blocked.
- Review the total authorized share count to ensure sufficient shares exist for the potential issuance of up to 133 million new shares.
- Monitor for any announcements regarding reverse stock splits, which would alter the conversion economics and trigger the $1.00 price floor.
- Check for any subsequent filings regarding the status of the stockholder approval process for these conversions.